What precautions should be taken for dental procedures in a patient receiving denosumab (Prolia)?

Dental Work Precautions for Patients on Prolia (Denosumab)

All patients receiving Prolia must undergo a comprehensive oral examination and complete any necessary invasive dental procedures BEFORE starting therapy, and invasive dental surgery (extractions, implants) should be avoided during active treatment. 1, 2, 3

Pre-Treatment Dental Assessment

Before initiating Prolia, patients require:

• Complete dental examination including periodontal assessment and radiographs
• Immediate treatment of any existing dental pathology
• Completion of all medically necessary extractions, implants, or other invasive procedures with full mucosal healing confirmed before starting denosumab 4

The rationale is clear: osteonecrosis of the jaw (MRONJ) occurs in 1-2% of patients on oncologic doses of denosumab, with most cases triggered by invasive dental procedures 1. For osteoporosis doses (60 mg every 6 months), the risk is lower (0-1%) but still significantly higher than with oral bisphosphonates 2.

During Active Treatment

Avoid all elective invasive dental procedures including:

• Tooth extractions
• Dental implant placement
• Alveoloplasties
• Other dentoalveolar surgery 2, 4

Maintenance Requirements:

• Maintain excellent oral hygiene throughout treatment
• Regular dental evaluations every 6 months once therapy begins 1
• Ensure well-fitting dentures to avoid mucosal trauma 4

If Invasive Dental Surgery Becomes Necessary

When unavoidable dental surgery must be performed during treatment:

1. Defer the next Prolia dose until complete healing occurs (though evidence for this is insufficient, it may be considered at physician discretion) 4

2. Suspend Prolia administration until the dentist confirms complete mucosal healing of the surgical site 3

3. Use prophylactic antibiotics when tooth extraction cannot be avoided 3

4. Schedule frequent follow-up every 6-8 weeks with a dental specialist experienced in MRONJ management until full mucosal coverage is achieved 4

5. Communicate closely between dentist and prescribing physician regarding healing status 4

Critical Caveat About Drug Holidays

A "drug holiday" does NOT reliably prevent MRONJ. Research shows no significant difference in MRONJ occurrence between patients who discontinued denosumab before tooth extraction and those who did not 5. Unlike bisphosphonates that accumulate in bone, denosumab does not persist in bone tissue, and interrupting therapy carries risks including rapid rebound bone loss and increased vertebral fracture risk 3.

Risk Factors That Increase MRONJ Risk

Higher risk patients include those with:

• Pre-existing dental inflammation or infection (OR 243.77) 5
• Periapical periodontitis (OR 14.13) 5
• Concurrent corticosteroid therapy (OR 73.50) 5
• Longer duration of denosumab therapy 5
• Multiple tooth extractions (OR 1.35 per additional extraction) 6
• Poor oral hygiene or uncontrolled diabetes 4

The risk with osteoporosis-dose denosumab (60 mg every 6 months) is approximately 2.3% after dental extractions—7.7 times higher than oral bisphosphonates 6.

Practical Algorithm

Before starting Prolia: → Complete dental exam → Treat all pathology → Complete invasive procedures → Confirm healing → Start Prolia

During Prolia treatment: → Maintain oral hygiene → 6-month dental checks → Avoid elective invasive procedures

If emergency dental surgery needed: → Consult dental specialist with MRONJ expertise → Consider deferring next dose → Perform surgery with antibiotics → Follow every 6-8 weeks → Resume Prolia only after complete healing

Supplementation throughout: Calcium and vitamin D to prevent hypocalcemia (more common with denosumab at 13% vs 6% with bisphosphonates) 1

This approach prioritizes preventing the serious morbidity of MRONJ while maintaining the fracture-prevention benefits of denosumab therapy.